

What is claimed is:

546 a1

1. A method of making a transgenic fusion protein comprising providing a transgenic animal which includes a transgene which provides for the expression of the fusion protein; allowing the transgene to be expressed; and, recovering the fusion protein, from the milk of the transgenic animal.
2. The method of claim 1, wherein the fusion protein includes an immunoglobulin-subunit and an enzyme.
3. The method of claim 1, wherein the fusion protein includes a first member fused to a second member and the first member includes the subunit of a targeting molecule and the second member encodes a cell toxin.
4. The method of claim 1, wherein the fusion protein includes a subunit of an Ig specific for a tumor antigen .
5. The method of claim 4, wherein the tumor antigen is from the group carcinoembryonic antigen (CEA), a transferring receptor, TAG-72, an epidermal growth factor receptor.
6. The method of claim 1, wherein the fusion protein includes an Rnase.
7. The method of claim 6, wherein the Rnase is RnaseA.
8. ~~The method of claim 1, wherein the fusion protein includes angiogenin.~~
9. The method of claim 1, wherein the fusion protein includes carboxypeptidase B enzyme.

25

546 a2

sub 23

10. The method of claim 1, wherein the fusion protein is made in a mammary gland of the transgenic mammal.
11. The method of claim 1, wherein the fusion protein is secreted into the milk of a transgenic mammal at concentrations of at least about 0.5 mg/ml or higher.
12. The method of claim 1, wherein the fusion protein is secreted into the milk of a transgenic mammal at concentrations of at least about 1.0 mg/ml or higher.
13. The method of claim 1, the immunoglobulin subunit of a fusion protein is a humanized antibody.
14. The method of claim 1, wherein the transgene encoding the transgenic fusion protein is a nucleic acid construct which includes:
- (a) optionally, an insulator sequence;
  - (b) a mammary epithelial specific promoter;
  - (c) a nucleotide sequence which encodes a signal sequence which can direct the secretion of the fusion protein, e.g. a signal from a milk specific protein;
  - (d) optionally, a nucleotide sequence which encodes a sufficient portion of the amino terminal coding region of a secreted protein, e.g. a protein secreted into milk, to allow secretion, e.g., in the milk of a transgenic mammal, of the fusion protein;
  - (e) one or more nucleotide sequences which encode the fusion protein; and
  - (f) optionally, a 3' untranslated region from a mammalian gene.
15. An isolated nucleic acid construct, which includes:
- (a) optionally, an insulator sequence;
  - (b) a mammary epithelial specific promoter;
  - (c) a nucleotide sequence which encodes a signal sequence which can direct the secretion of the fusion protein, e.g. a signal sequence from a milk specific protein;

(d) optionally, a nucleotide sequence which encodes a sufficient portion of the amino terminal coding region of a secreted protein, e.g. a protein secreted into milk, to allow secretion, e.g., in the milk of a transgenic mammal, of fusion protein;

(e) one or more nucleotide sequences which encode a fusion protein as described in  
5 claim 1; and

(f) optionally, a 3' untranslated region from a mammalian gene, e.g., a mammary epithelial specific gene, (e.g., a milk protein gene).

In another aspect, the invention features, a pharmaceutical or nutraceutical composition having an effective amount of fusion protein, e.g., an immunoglobulin-enzyme  
10 fusion protein as described herein, and a pharmaceutically acceptable carrier.

In a preferred embodiment, the composition includes milk.

*624*  
*rule 100* *16*  
*101 human*  
15 A transgenic animal which includes a transgene that encodes a fusion protein described in claim.

*17*  
16. The transgenic animal of claim 15, which can secrete the fusion protein into its milk at concentrations of at least about 0.5 mg/ml or higher.

*add 25*